NEW RIVER PHARMACEUTICALS INC - NRPH Unscheduled Material Events (8-K) EXHIBIT 99.1

The following is an excerpt from a 8-K SEC Filing, filed by NEW RIVER PHARMACEUTICALS ... on 2/7/2006.

Jump to :

Exhibit 99.1
[[Image Removed]] Exhibit 99.1
Merrill Lynch Healthcare Conference 2006 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO)

[[Image Removed]] Forward Looking Statements
This presentation may contain forward-looking statements that reflect managements current views as to the Companys clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statements involve uncertainties and risks that are detailed in the Companys Annual Report on Form 10-K filed with the SEC on April 1, 2005, as well as other public filings with the SEC. Actual results could differ materially from these forward-looking statements.

[[Image Removed]] A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and shorter development pathway, facing timely market demand, in a favorable regulatory climate. Investment Thesis

[[Image Removed]] n
NRP104
New Drug Application (NDA) on NRP104 accepted by the FDA $50 million milestone payment received from Shire Pharmaceuticals 2 of 3 clinical abuse liability studies completed and met desired objectives Remaining study is ongoing and will be submitted during the review cycle n
NRP290
Second Phase I/II study completed
n
NRP388
IND on NRP388 anticipated by end of 2Q 2006 n
NRP409
Preclinical studies to date met desired objectives IND on NRP409 anticipated by end of 2Q 2006 Pipeline Update

[[Image Removed]]
NRP290

[[Image Removed]]
NRP290
n
A conditionally bioreversible derivative of hydrocodone n
Potential indications: pain (moderate to moderately severe) n
Non-clinical studies to date have met their desired objectives n
Second Phase I/II PK clinical study on NRP290 completed n
Difficult to recover/extract hydrolyzed hydrocodone based on results to date

[[Image Removed]] Treatment A Test formulation (NRP290); Dose = 1 x 12 mg solution; 1 x 500 mg acetaminophen
tablet
Treatment B Test formulation (NRP290); Dose = 1 x 24 mg solution; 2 x 500 mg acetaminophen
tablet
Treatment C Reference Product (Vicodin®); Dose = 1 x 5/500 mg tablet Treatment D Reference Product (Vicodin®); Dose = 2 x 5/500 mg tablet

A Single-Dose, 4-Treatment, 4-Period, Crossover Pharmacokinetic Study to Assess Relative Bioavailability of Two Investigational Formulations of NRP290 (1 x 12 mg and 1 x 24 mg) solution versus Vicodin® (1 x 5/500 mg and 2 x 5/500 mg) Tablet in Fasted State Healthy Adult Volunteers. NRP290: Multi-Dose Study

[[Image Removed]] NRP290: Second Phase I study
n
Comparing hydrocodone from NRP290 (1x12mg) to Vicodin®(1x5/500mg) The 90% confidence intervals for peak and overall exposure parameters of hydrocodone based on ln(Cmax), ln(AUClast) and ln(AUCinf) were within 80% to 125%. Therefore, a single dose of NRP290 12 mg is bioequivalent to the single dose of Vicodin® 5/500 mg under fasting conditions. n
Comparing hydrocodone from NRP290 (1x24mg) to Vicodin®(2x5/500mg) The 90% confidence intervals for peak of hydrocodone based on ln(Cmax) was within 80% to 125%. The upper limit of 90% confidence intervals for overall exposure parameters of hydrocodone based on ln(AUClast) and ln(AUCinf) were slightly higher(128.51% and 134.67%). n
Intact NRP290 conjugates
No intact NRP290 conjugates observed in systemic circulation in either dose.

[[Image Removed]] NRP290: Next Steps
n
Finalize Formulation on NRP290 (with and without APAP) n
Request End-of-Phase 2 meeting with FDA in Q2/Q3 2006 to finalize efficacy and safety studies and define regulatory strategy

[[Image Removed]]